SERD – Medxy AI

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

By MedXY 10/24/2025

Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survival trends.

news

创新口服SERD联合依维莫司疗法在晚期ER+ HER2-乳腺癌中显示优越疗效

By MedXY 10/24/2025

罗氏宣布giredestrant联合依维莫司的III期研究结果积极，显著降低之前接受过CDK4/6抑制剂治疗的ER+ HER2-晚期乳腺癌患者的疾病进展风险，且具有良好的安全性和生存趋势。

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance

By MedXY 08/07/2025

Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profiles.